Tag Archives: Tandem

Tandem Hosts 2021 R&D Webinar; FDA Accepts IND for G&L’s Novel GLP-1 Analogue; BD Announces Name of Diabetes Spin Off Company

Three cardiometabolic-related news items have been observed: Tandem hosted its 2021 R&D webinar (view here; slides) and provided an in-depth review of the company’s product pipeline, including the t:slim X3, t:sport (Mobi), and a future patch pump; Gan & Lee announced FDA accepted its IND application for a novel GLP-1 analog, referred to as GZR18; and Becton Dickinson announced that its diabetes spinoff business company will be named “embecta [pronounced em-BECK-tah]. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Already a member? Log in here

Lexicon, Tandem, Amarin, Intercept, and Amgen Q3 ’21 Earnings Updates

A series of cardiometabolic-related news items have been observed: Lexicon (press release), Tandem (press release), Amarin (press release; slides), Intercept, (press release; slides), and Amgen (press release; slides), hosted their respective Q3 ’21 earnings calls. Importantly, Lexicon discussed its US sotagliflozin commercial strategy suggesting it is moving forward on its own. Below, FENIX provides highlights and insights from the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Tandem, Ionis, Esperion, and Amgen Q2 ’21 Earnings Updates; Dario Gains National Digital Behavioral Health Contract

Five cardiometabolic-related news items have recently been observed: Tandem, Ionis, Esperion, and Amgen hosted their respective Q2 ‘21 earnings calls; and Dario Health announced it was selected as the digital behavioral health provider for an undisclosed national professional services company. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Tandem, Lannett, Esperion, and Ionis Q1 ’21 Earnings Updates; Nemaura Receives Order for its Non-invasive CGM

A series of cardiometabolic-related news items have recently been observed: Tandem, Lannett, Esperion, and Ionis hosted their respective Q1 ’21 earnings calls; and Nemaura Medical announced it received an order from its UK licensee, DB Ethitronix Ltd, of 5,000 sugarBEAT transmitters and 200,000 sugarBEAT sensors. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

BI and Gubra Partner for Obesity Drug Development; Diabeloop DBLG1 Integrates with Accu-Chek Insight Pump; Tandem Appoints Jordan Pinsker as VP and Medical Director

A series of cardiometabolic-related news items have been observed: Boehringer Ingelheim and Gubra announced a research and licensing agreement for discovering and evaluating targets and innovative peptide compounds for the treatment of obesity; Diabeloop announced the integration of the Accu-Chek Insight insulin pump into the DBLG1 System; Tandem announced Jordan Pinsker from Sansum has been appointed as VP and Medical Director. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Tandem and Teladoc Q4 and FY ’20 Earnings Updates

Tandem and Teladoc hosted their Q4 and FY ’20 earnings calls and provided updates on their respective businesses. Importantly, Tandem disclosed that the development of its next-gen t:sport pump platform has been delayed by one quarter. Below, FENIX provides highlights and insights from the respective calls.

This content is for Read Less members only.
Already a member? Log in here

Tandem Q3 ’20 Earnings Update

Tandem Diabetes Care hosted its Q3 ’20 earnings call (press release) and provided updates to its business, including the recent 510(k) filing for the t:slim X2 remote bolus feature. Below, FENIX provides highlights and insights from the call.

This content is for Read Less members only.
Already a member? Log in here

Tandem Q2 ’20 Earnings Update

Tandem Diabetes Care hosted its Q2 ’20 earnings call (press release) and provided updates to key commercial and clinical activities including its curious partnership with Medtronic (previous FENIX insight), t:connect app launch, partnership with Abbott, and more. Below, FENIX provides highlights and insights from the call.

This content is for Read Less members only.
Already a member? Log in here

Tandem Partners with JDRF for Diabetes Device Education Campaign; Livongo’s myStrength App Available for Free to Priority Health Members

Two diabetes-related news items have been observed: Tandem announced it is partnering with JDRF for a national T1DM educational awareness campaign focusing on diabetes technology and Priority Health is providing Livongo’s myStrength mental health app for free to its members. Below, FENIX provides insights into the respective news items, notably the timing of the Tandem/JDRF collaboration given the recent favorable reimbursement decision by UnitedHealthcare (previous FENIX insight).

This content is for Read Less members only.
Already a member? Log in here

UnitedHealth to Cover Tandem Pumps

Several equity research analyst sources are reporting UnitedHealth Group is now covering Tandem’s insulin pumps (view article here). Although an official policy document from UnitedHealth (UNH) could not be found in a timely manner, FENIX provides brief thoughts on the United coverage in the context of the previous exclusive agreement between United/Medtronic as well as Tandem’s recent FDA pediatric approval for Control IQ.

This content is for Read Less members only.
Already a member? Log in here